Vista Pharma Q3FY26: Revenue Declines and Net Loss Widens
Vista Pharmaceuticals Ltd 路 Outcome 路 13 Feb 2026, 8:56 pm
Vista Pharma Q3FY26: Revenue Declines and Net Loss Widens Vista Pharmaceuticals reported a widened Net Loss of Rs 231.94 lakhs for the quarter ended 31 Dec'25, compared to a loss of Rs 132.23 lakhs YoY. Revenue from operations declined 5.4% YoY to Rs 241.82 lakhs. The loss before tax increased to Rs 328.04 lakhs from Rs 180.44 lakhs YoY, impacted by higher expenses. Notably, the company recognized an Expected Credit Loss provision of Rs 205.43 lakhs against long-pending trade receivables. Basic EPS for the quarter stood at Rs (0.41).
Original exchange filing (PDF)
More announcements from Vista Pharmaceuticals Ltd
- Resignation of Company Secretary & Compliance Officer 路 12 Sept 2026
- Results for the quarter ended 30.06.2026 路 14 Aug 2026
- Results for the quarter ended 30.06.2026 路 14 Aug 2026
- Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve 1. Unaudited financial .... 路 14 Aug 2026
- Board meeting outcome 路 29 May 2026
- Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve 1. Audited financial .... 路 29 May 2026
- <b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> .... 路 29 Apr 2026
- Results for the quarter ended 31.12.2025 路 13 Feb 2026
